Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCND3 | P30281 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480711 | 0.88 | PSEN1 (0.34) | LMNATSHRHSD17B10 | |
| SCHEMBL3480722 | 0.87 | LMNA (0.34) | LMNATSHR | |
| SCHEMBL3480710 | 0.87 | LMNA (0.32) | LMNATSHRHSD17B10 | |
| SCHEMBL3480880 | 0.86 | EGFR (0.39) | CDK2 | |
| SCHEMBL8167298 | 0.86 | LMNA (0.34) | LMNATSHRHSD17B10CDK2 | |
| SCHEMBL3480691 | 0.80 | ALK (0.37) | — | |
| SCHEMBL3480705 | 0.80 | BCL6 (0.35) | — | |
| SCHEMBL3480686 | 0.77 | EGFR (0.41) | CDK2 | |
| SCHEMBL3480868 | 0.75 | EGFR (0.39) | CDK2 | |
| SCHEMBL3480728 | 0.75 | EGFR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| WO-2008100412-A1 | PIPERIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | PSEN1, PSEN2, APBA1 | LMNA 3680/4885TSHR 4345/4885HSD17B10 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.